Evaluation of mutagenic and genotoxic activities of lobeline and its modulation on genomic instability induced by ethanol

Silva, Liana Dantas da Costa e; Rodrigues, Laise Carla Lima Verde; Santos, Viviane Ramos dos; Allgayer, Mariângela da Costa; Ferraz, Alexandre de Barros Falcão; Rolla, Helena Campos; Pereira, Patrı́cia; Picada, Jaqueline Nascimento

doi:10.1016/j.lfs.2014.03.034

Cited by 7 publications

(4 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a pre-clinical trial, lobeline, a natural alkaloid derived from Lobelia inflate, decreased the preference for alcohol intake through the modulation of the nicotinic acetylcholine receptor. When assayed for its mutagenic and genotoxic effects (5 or 10 mg/kg) and ethanol (2.5 g/kg), it was found safe and the biochemical parameters were not altered, indicating the safety of lobeline to treat alcohol dependence (da Costa et al, 2014).…”

Section: Novel Aud Medications and Their Signaling Pathwaysmentioning

confidence: 99%

Medications for alcohol use disorders: An overview

Akbar

Egli

Cho

et al. 2018

Pharmacology & Therapeutics

View full text Add to dashboard Cite

Patients who suffer from alcohol use disorders (AUDs) usually go through various socio-behavioral and pathophysiological changes that take place in the brain and other organs. Recently, consumption of unhealthy food and excess alcohol along with a sedentary lifestyle has become a norm in both developed and developing countries. Despite the beneficial effects of moderate alcohol consumption, chronic and/or excessive alcohol intake is reported to negatively affect the brain, liver and other organs, resulting in cell death, organ damage/failure and death. The most effective therapy for alcoholism and alcohol related comorbidities is alcohol abstinence, however, chronic alcoholic patients cannot stop drinking alcohol. Therefore, targeted therapies are urgently needed to treat such populations. Patients who suffer from alcoholism and/or alcohol abuse experience harmful effects and changes that occur in the brain and other organs. Upon stopping alcohol consumption, alcoholic patients experience acute withdrawal symptoms followed by a protracted abstinence syndrome resulting in the risk of relapse to heavy drinking. For the past few decades, several drugs have been available for the treatment of AUDs. These drugs include medications to reduce or stop severe alcohol withdrawal symptoms during alcohol detoxification as well as recovery medications to reduce alcohol craving and support abstinence. However, there is no drug that completely antagonizes the adverse effects of excessive amounts of alcohol. This review summarizes the drugs which are available and approved by the FDA and their mechanisms of action as well as the medications that are under various phases of preclinical and clinical trials. In addition, the repurposing of the FDA approved drugs, such as anticonvulsants, antipsychotics, antidepressants and other medications, to prevent alcoholism and treat AUDs and their potential target mechanisms are summarized.

show abstract

Section: Novel Aud Medications and Their Signaling Pathwaysmentioning

confidence: 99%

Medications for alcohol use disorders: An overview

Akbar

Egli

Cho

et al. 2018

Pharmacology & Therapeutics

View full text Add to dashboard Cite

show abstract

“…Lobeline (5–10 mg/kg i.p. ), an alkaloid isolated from Lobelia inflata , had no genotoxic or mutagenic effects in the comet assay, the micronucleus test in bone marrow, or the Salmonella/microsome mutagenic assay [ 99 ].…”

Section: Toxicologymentioning

confidence: 99%

“…Lobeline (5–10 mg/kg i.p.) did not affect the levels of AST, ALT, ALP, and LDH after 4 days of exposure [ 99 ].…”

Section: Toxicologymentioning

confidence: 99%

Medicinal Plants from North and Central America and the Caribbean Considered Toxic for Humans: The Other Side of the Coin

Alonso-Castro

Domínguez

Ruiz-Padilla

et al. 2017

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

The consumption of medicinal plants has notably increased over the past two decades. People consider herbal products as safe because of their natural origin, without taking into consideration whether these plants contain a toxic principle. This represents a serious health problem. A bibliographic search was carried out using published scientific material on native plants from Mexico, Central America, and the Caribbean, which describe the ethnobotanical and toxicological information of medicinal plants empirically considered to be toxic. A total of 216 medicinal plants belonging to 77 families have been reported as toxic. Of these plants, 76 had been studied, and 140 plants lacked studies regarding their toxicological effects. The toxicity of 16 plants species has been reported in clinical cases, particularly in children. From these plants, deaths have been reported with the consumption of Chenopodium ambrosioides, Argemone mexicana, and Thevetia peruviana. In most of the cases, the principle of the plant responsible for the toxicity is unknown. There is limited information about the toxicity of medicinal plants used in Mexico, Central America, and the Caribbean. More toxicological studies are necessary to contribute information about the safe use of the medicinal plants cited in this review.

show abstract

“…Damage frequency (DF) was calculated based on number of cells with tail versus those with no tails. 14,15 Hydrogen peroxide (H 2 O 2 ) of 0.25 mM concentration was used as the positive control.…”

Section: Comet Assaymentioning

confidence: 99%

Genotoxic and mutagenic effects of vigabatrin, a γ-aminobutyric acid transaminase inhibitor, in Wistar rats submitted to rotarod task

et al. 2016

View full text Add to dashboard Cite

Vigabatrin (VGB) is an antiepileptic drug thatincreases brain γ-aminobutyric acid (GABA) levels through irreversible inhibition of GABA transaminase. The aim of this study was to evaluate neurotoxicological effects of VGB measuring motor activity and genotoxic and mutagenic effects after a single and repeated administration. Male Wistar rats received saline, VGB 50, 100, or 250 mg/kg by gavage for acute and subchronic (14 days) treatments and evaluated in the rotarod task. Genotoxicity was evaluated using the alkaline version of the comet assay in samples of blood, liver, hippocampus, and brain cortex after both treatments. Mutagenicity was evaluated using the micronucleus test in bone marrow of the same animals that received subchronic treatment. The groups treated with VGB showed similar performance in rotarod compared with the saline group. Regarding the acute treatment, it was observed that only higher VGB doses induced DNA damage in blood and hippocampus. After the subchronic treatment, VGB did not show genotoxic or mutagenic effects. In brief, VGB did not impair motor activities in rats after acute and subchronic treatments. It showed a repairable genotoxic potential in the central nervous system since genotoxicity was observed in the acute treatment group.

show abstract

Evaluation of mutagenic and genotoxic activities of lobeline and its modulation on genomic instability induced by ethanol

Cited by 7 publications

References 47 publications

Medications for alcohol use disorders: An overview

Medications for alcohol use disorders: An overview

Medicinal Plants from North and Central America and the Caribbean Considered Toxic for Humans: The Other Side of the Coin

Genotoxic and mutagenic effects of vigabatrin, a γ-aminobutyric acid transaminase inhibitor, in Wistar rats submitted to rotarod task

Contact Info

Product

Resources

About